Cartesian Therapeutics — Biomedical Watch V2

Traitements6programmes

Essais4liés

Publications3liées

SourceDBlocale

Traitements

6

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Decartes-08The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.	Myasthénie	Phase 3	Thérapie cellulaire	United States, Canada, Italy, Poland, Serbia, Spain, Turkey (Türkiye), United Kingdom	À vérifier
Descartes-08This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis	Lupus, Myasthénie, Myopathies	Phase 2	À vérifier	United States, Canada	À vérifier
Descartes-08This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis	Myasthénie	Phase 2	Thérapie cellulaire + Immunomodulation	United States, Canada	À vérifier
Descartes-08This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis	Lupus	Phase 1/2		United States	À vérifier
Descartes-08This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis	Myopathies	Phase 2	À vérifier	United States	À vérifier
Decartes-08The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.	Myasthénie	Phase 3	Thérapie cellulaire	United States, Canada, Italy, Poland, Serbia, Spain, Turkey (Türkiye), United Kingdom	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
Decartes-08	Myasthénie	Phase 3	NCT06799247	Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis	ACTIVE_NOT_RECRUITING
Descartes-08	Myopathies	Phase 2	NCT07391605	Descartes-08 in Autoantibody Myositis	RECRUITING
Descartes-08	Lupus	Phase 1/2	NCT07089121	Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders	RECRUITING
Descartes-08	Myasthénie	Phase 2	NCT04146051	Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)	ACTIVE_NOT_RECRUITING

Publications

3

Molécule	Indication / population	Titre	Journal	Date
Descartes-08		BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.	Nature medicine
Descartes-08		BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.	Nature medicine
Descartes-08		Descartes-08: Unlocking the potential of mRNA CAR T-cell therapy in myasthenia gravis.	Molecular therapy : the journal of the American Society of Gene Therapy